Medicaid best price reforms to enable innovative payment models for cell and gene therapies

Eric NormanFoCUS, Publications

Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.
Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M.

Cell and gene therapies promise durable benefits but face financial challenges from the uncertainty in their performance. Value-based purchasing arrangements (VBPAs) can address uncertainty but have been inhibited in the US by the Medicaid Drug Rebate Program (MDRP) approach to determining Medicaid Best Price (MBP) rebates. The likely effectiveness of MDRP reform proposals enabling VBPAs is examined in this study for durable cell and gene therapies.

Read the publication